| Literature DB >> 29564572 |
Adnane Aouidate1, Adib Ghaleb2, Mounir Ghamali2, Samir Chtita2, Abdellah Ousaa2, M'barek Choukrad2, Abdelouahid Sbai2, Mohammed Bouachrine3, Tahar Lakhlifi2.
Abstract
BACKGROUND: Quantitative structure-activity relationship (QSAR) was carried out to study a series of aminooxadiazoles as PIM1 inhibitors having pki ranging from 5.59 to 9.62 (k i in nM). The present study was performed using Genetic Algorithm method of variable selection (GFA), multiple linear regression analysis (MLR) and non-linear multiple regression analysis (MNLR) to build unambiguous QSAR models of 34 substituted aminooxadiazoles toward PIM1 inhibitory activity based on topological descriptors.Entities:
Keywords: Aminooxadiazoles; Applicability domain; MLR; PIM1; QSAR model; Virtual screening
Year: 2018 PMID: 29564572 PMCID: PMC5862716 DOI: 10.1186/s13065-018-0401-x
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Fig. 1The chemical structure of the studied compounds
Observed activities of studied aminooxadiazoles
*Test set
The values of three relevant molecular descriptors used in the best QSAR model
| No |
| SpMin6_Bhm | MLogP | SpMax1_Bhi | No |
| SpMin6_Bhm | MLogP | SpMax1_Bhi |
|---|---|---|---|---|---|---|---|---|---|
|
| 8.769 | 1.276 | 2.67 | 4.187 |
| 8.522 | 1.352 | 2.890 | 4.225 |
|
| 5.591 | 0.707 | 2.01 | 4.135 |
| 6.943 | 1.228 | 2.889 | 4.172 |
|
| 7.259 | 1.276 | 2.889 | 4.188 |
| 7.494 | 1.372 | 3.330 | 4.190 |
|
| 8.677 | 1.361 | 2.78 | 4.188 |
| 8.080 | 1.372 | 3 | 4.191 |
|
| 8.522 | 1.266 | 2.45 | 4.187 |
| 6.600 | 1.364 | 3.11 | 4.190 |
|
| 8.795 | 1.361 | 2.56 | 4.188 |
| 6.939 | 1.350 | 3.329 | 4.194 |
|
| 9.284 | 1.349 | 2.449 | 4.188 |
| 9.619 | 1.334 | 2.449 | 4.190 |
|
| 8.853 | 1.286 | 2.56 | 4.189 |
| 9.075 | 1.340 | 2.89 | 4.190 |
|
| 6.823 | 1.015 | 2.23 | 4.186 |
| 8.920 | 1.372 | 2.89 | 4.190 |
|
| 8.699 | 1.295 | 2.56 | 4.190 |
| 8.657 | 1.341 | 2.78 | 4.190 |
|
| 7.508 | 1.015 | 2.01 | 4.188 |
| 9.259 | 1.341 | 3 | 4.190 |
|
| 8.677 | 1.278 | 2.89 | 4.194 |
| 7.161 | 1.350 | 3.11 | 4.190 |
|
| 7.832 | 1.276 | 2.78 | 4.187 |
| 8.886 | 1.338 | 2.78 | 4.191 |
|
| 8.568 | 1.361 | 2.78 | 4.188 |
| 9.346 | 1.349 | 2.78 | 4.192 |
|
| 8.958 | 1.361 | 2.78 | 4.188 |
| 8.795 | 1.341 | 2.78 | 4.192 |
|
| 7.284 | 1.360 | 3.11 | 4.226 |
| 7.267 | 1.249 | 2.45 | 4.188 |
|
| 8.522 | 1.276 | 2.67 | 4.187 |
| 8.920 | 1.335 | 2.78 | 4.195 |
* Test set
Multi-colinearity test
| Variables | SpMin6_Bhm | MLogP | SpMax1_Bhi |
|---|---|---|---|
| VIF | 3.035 | 2.201 | 1.869 |
Observed values and calculated values of pki according to different methods
| No | |||
|---|---|---|---|
| MLR | MNLR | ||
|
| 8.769 | 8.345 | 8.328 |
|
| 5.591 | 5.358 | 5.535 |
|
| 7.259 | 7.916 | 8.045 |
|
| 8.677 | 8.838 | 9.037 |
|
| 8.522 | 8.695 | 8.261 |
|
| 8.795 | 9.272 | 9.197 |
|
| 9.284 | 9.383 | 9.036 |
|
| 8.853 | 8.629 | 8.514 |
|
| 6.823 | 7.021 | 7.510 |
|
| 8.699 | 8.694 | 8.595 |
|
| 7.508 | 7.429 | 6.996 |
|
| 8.677 | 7.880 | 8.171 |
|
| 7.832 | 8.143 | 8.186 |
|
| 8.568 | 8.838 | 9.024 |
|
| 8.958 | 8.838 | 9.024 |
|
| 7.284 | 7.824 | 7.648 |
|
| 8.522 | 8.192 | 8.241 |
|
| 6.943 | 7.664 | 7.010 |
|
| 7.494 | 7.852 | 7.486 |
|
| 8.080 | 8.481 | 8.772 |
|
| 6.600 | 8.211 | 8.299 |
|
| 6.939 | 7.623 | 7.309 |
|
| 9.619 | 9.235 | 8.919 |
|
| 9.075 | 8.439 | 8.655 |
|
| 8.920 | 8.706 | 9.016 |
|
| 8.657 | 8.653 | 8.856 |
|
| 9.259 | 8.228 | 8.390 |
|
| 7.161 | 8.092 | 8.144 |
|
| 8.886 | 8.621 | 8.856 |
|
| 9.346 | 8.708 | 8.984 |
|
| 8.795 | 8.641 | 8.909 |
|
| 7.267 | 8.544 | 8.174 |
|
| 8.920 | 8.556 | 8.902 |
|
| 8.522 | 8.785 | 8.804 |
* Test set
Fig. 2Graphical representation of predicted and observed activity (pki) values calculated by MLR
Fig. 3Graphical representation of predicted and observed activity (pk) values calculated by MNLR
Fig. 4Williams plot for the training set and external validation for the PIM1 inhibitory activity of aminooxadiazole compounds, listed in Table 1 (h* = 0.44 and residual limits ± 2)
Q2 and R2 values after several Y-Randomization tests
| Iteration | MLR | MNLR | ||
|---|---|---|---|---|
| Q2 | R2 | Q2 | R2 | |
| 1 | 0.390 | 0.235 | 0.031 | 0.350 |
| 2 | 0.120 | 0.094 | 0.095 | 0.008 |
| 3 | 0.290 | 0.124 | 0.079 | 0.190 |
| 4 | 0.340 | 0.129 | − 0.264 | 0.290 |
| 5 | 0.180 | 0.263 | − 0.160 | 0.335 |
| 6 | 0.160 | 0.194 | − 0.522 | 0.140 |
| 7 | 0.20 | 0.075 | − 0.105 | 0.006 |
| 8 | 0.130 | 0.043 | 0.230 | 0.026 |
| 9 | 0.140 | 0.116 | 0.120 | 0.196 |
| 10 | 0.230 | 0.031 | 0.060 | 0.131 |
The statistical results of MLR and MNLR models with validation techniques
| Method/parameter |
|
|
|
| MSE |
|---|---|---|---|---|---|
| MLR | 0.838 | 0.712 | 0.60 | 0.81 | 0.29 |
| MNLR | 0.910 | 0.812 | 0.56 | 0.75 | 0.22 |
Predicted values and calculated h of pk (k in nM) of the sixteen identified hits
Fig. 5Reference structure of aminooxadiazole model with lowest binding constant ki
Fig. 6Leverage values of the screened compounds from the PubChem database for the PIM1 inhibitory activity, listed in Table 7 (h* = 0.44)